



Feraheme® (ferumoxytol) – First-time generic

- On July 16, 2021, Sandoz launched an AB-rated generic version of AMAG Pharmaceuticals' Feraheme (ferumoxytol) injection.
- Feraheme is approved for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have chronic kidney disease.
- Feraheme carries a boxed warning for risk for serious hypersensitivity/ anaphylaxis reactions.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.